News about 'r&d'

Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...

We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort , Lucca (Barga), Italy. The workshop is held in conjunction with the Gordon Conference...

Vilchèze C, Hartman T, Weinrick B, and Jacobs W. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction . Nature Communications. 2013 May 21; 4(1881). doi:10.1038/ncomms2898 Abstract: Drugs that kill tuberculosis more quickly could shorten...

Update: Release of Part 1 of EXPOSED scheduled for the week of May 20. Contact jrosen@aeras.org if you would like to host a screening event or get more information. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will...

Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access , 2) on adaptive clinical trial designs , and 3) on pediatric drug development needs . The full...

Click to access links and audio from Lancet ID TB Edition Executive Summary To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO. Without...

Yesterday, Nov. 28th, the FDA Ant-infective Drug Advisory Committee voted to recommend Janssen ‘s Bedaquiline for accelerated approval for the treatment of MDR tuberculosis. You can access materials from the meeting at http://www.fda.gov/AdvisoryCommittees/Calendar/ucm321011.htm . The sponsor and...

This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.

Anna K. Coussensa, Robert J. Wilkinson, Yasmeen Hanifa, Vladyslav Nikolayevskyy, Paul T. Elkington, Kamrul Islam, Peter M. Timms, Timothy R. Venton, Graham H. Bothamley, Geoffrey E. Packe, Mathina Darmalingam, Robert N. Davidson, Heather J. Milburn, Lucy V. Baker, Richard D. Barker, Charles A. Mein...

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS...

We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ 2012 Annual Meeting at the Impiana KLCC Hotel in Kuala Lumpur, Malaysia on Wednesday, November 14. Also, we are sponsoring a lunch to allow the Sub-groups (Biology/Targets, Candidates, Critical Knowledge and Tools, and...

Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet . The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than...

Structure of Bedaquiline This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207). For additional information on...

Delamanid (OPC-67683) This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine ...

For this week’s update, we highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Dooley KE, Mitnick C, Degroote MA, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N,...